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ABSTRACT Dermatan sulfate, an important member of the glycosaminoglycan
family,interactswithheparincofactorII,amemberoftheserpinfamilyofproteins,
to modulate antithrombotic response. Yet, the nature of this interaction remains
poorly understood at a molecular level. We report the genetic algorithm-based
combinatorial virtual library screening study of a natural, high-affinity dermatan
sulfate hexasaccharide with heparin cofactor II. Of the 192 topologies possible
for the hexasaccharide, only 16 satisfied the “high-specificity” criteria used in
computationalstudy.Ofthese,13topologieswerepredictedtobindintheheparin-
binding site of heparin cofactor II ata ∼60 angle tohelix D, a novel binding mode.
This new binding geometry satisfies all known solution and mutagenesis data and
supports thrombin ternary complexation through a template mechanism. The
study is expected to facilitate the design ofallosteric agonists of heparin cofactorII
as antithrombotic agents.
KEYWORDSComputationalbiology,dermatansulfate,glycosaminoglycans,heparin
cofactor II, serpins, structure-activity relationships
G
lycosaminoglycans (GAGs) play critical roles in a
numberofphysiologicalandpathologicalprocesses
such as hemostasis, inflammation, neural growth,
angiogenesis, and viral invasion. These roles arise from
their interaction with a multitude of proteins. Yet, the
structural elements that induce these interactions remain
elusive, except perhaps for the heparin-antithrombin (AT)
interaction.
1-3
A fundamental reason for this poor understanding is their
phenomenal structural diversity. GAGs are anionic copoly-
mers of glycosamine and uronic acid residues, which are
variously modified through sulfation, acetylation, and epi-
merization.Addedtothesevariationsarethemultiplehelical
structures adopted by polymeric GAG chains. For example,
dermatan sulfate (DS) can assume either 21-, 32-, or 83-fold
helix.
4 Further compounding the structural diversity is con-
formational flexibility of the constituent residues. For exam-
ple, iduronic acid (IdoAp), a residue present in DS and heparin,
exhibits four major conformers:
1C4,
4C1,
2SO,a n d
OS2.
5,6 This
combination of configurational and conformational varia-
tions leads to an exponential number of GAG topologies.
Asimplecalculationrevealsthat884736differenttopologies
are possible for a DS hexasaccharide, of which a select few
may induce a physiological response.
A potentially powerful approach to address GAG-protein
interactions is computational analysis. Yet, modeling GAGs
has been problematic due in part to their polyanionic nature
andpoorsurfacecomplementarity.
7,8Recently,wedeveloped
a combinatorial virtual library screening (CVLS) approach
using the genetic algorithm-based automated docking pro-
gram GOLD and a library of 6859 heparin hexasaccharide
sequences.
9 Application of the CVLS methodology to heparin
recognition of AT resulted in the identification of several
putative “high-affinity and high-specificity” heparin sequen-
ces as well as an accurately predicted description of the
binding mode of the heparin pentasaccharide H5 (Figure 1)
consistentwithexperimentallydeterminedH5-ATstructure-
activity relationships. The success of this approach for the
heparin-AT interaction pair suggests its possible use for its
sister pair, the DS-heparin cofactor II (HCII) system, which
remains structurally undefined and less well-understood at a
molecular level.
The DS-HCII system has a number of important phy-
siological roles.
10-13 HCII is a human plasma serine pro-
teinase inhibitor (serpin) that specifically inhibits throm-
bin,
14 ak e ye n z y m ep l a y i n gac r i t i c a lr o l ei nh e m o s t a s i s .
TheintrinsicspecificityofHCIImaybeauniqueadvantage
because its deficiency does not appear to enhance risk for
thrombosis.
15 A tt h es a m et i m e ,t h es e r p i np r e v e n t sa r t e r -
ial thrombosis.
11,12,15,16 HCII is also able to inhibit clot-
bound thrombin, in striking contrast to AT.
17 Despite these
advantages, no anticoagulant has yet been developed that
utilizes the HCII-based indirect pathway of coagulation
regulation.
Received Date: March 6, 2010
Accepted Date: June 6, 2010r2010 American Chemical Society 282 DOI: 10.1021/ml100048y|ACS Med. Chem. Lett. 2010, 1, 281–285
pubs.acs.org/acsmedchemlett
The inhibition of thrombin by HCII is accelerated nearly
1000-fold in the presence of DS. A rare DS hexasaccharide
D6 (Figure 1)has beenshowntobindHCII withhigh affinity,
while DS sequences with higher levels of sulfation bind
poorly, suggesting significant specificity of interaction.
18,19
On a three-dimensional level, HCII is structurally similar to AT.
For example, Lys114, Lys125, and Arg129, the three key
heparin-binding residues in AT, correspond to Lys173,
Lys185, and Arg189 of helix D in HCII. Likewise, Arg46,
Arg47, Arg132, and Lys133 of AT match Lys101, Arg103,
Arg192, and Arg193 of HCII. Yet, H5 (Figure 1), which
recognizes AT with high affinity and high specificity, binds
HCII poorly.
20 On the other hand, it is known that DS does
not interact with Arg103 and Lys173,
21,22 as one would
expect on the basis of the structural similarity of AT and
HCII. Overall, despite the availability of much biochemical
data, the structure of the DS-HCII complex remains un-
known and unexploited.
In this work, we predict the HCII binding geometry of the
high-affinity DS hexasaccharide D6 using the CVLS ap-
proach that we developed earlier.
9 To assess how D6 might
interact with HCII, we sought to prepare all possible topo-
logies of the hexasaccharide. Thus, using three possible
helical folds (21-, 32-, or 83-helices), four possible major
conformers(
1C4,
4C1,
2SO,and
OS2)for IdoAp, and the most
favoredconformerforgalactosamineresidue(GalNp)(
4C1),
192 topologies (3  4  4  4) were generated for D6 in a
combinatorial manner with SYBYL using in-house Sybyl
Programming Language (SPL) scripts. The crystal structure
ofthe activatedform ofHCII was extractedfrom theS195A
thrombin-HCII Michaelis complex (PDB entry 1JMO),
23
which is similar to that of activated AT.
24,25 Because of its
high degree of similarity to the heparin binding site in AT
and site-directed mutagenesis studies, the region formed
by helices A and D was predicted to be the binding site for
D6 in HCII.
Our CVLS approach to understand the interaction of D6
with HCII utilized a variation of the dual-filter docking and
scoring strategy tailored for the study of GAG-protein inter-
actions (Figure 2).
9 In this strategy, GOLD was used to
sample possible interaction poses and assess their fitness
to the GOLDScore function. GOLD utilizes a genetic algorith-
mic search in which an initial population of 100 randomly
dockedD6orientationsforeachtopologyisevaluatedbythe
scoring function and iteratively improved through a bias for
higher scores. The top-ranked solutions for each topology
were then subjected to a “specificity” filter in which self-
consistency of docking, when performed multiple times,
wasassessed.Thetoptwosolutionsfromthreeindependent
docking runs (six solutions total) were compared. D6 topol-
ogies that had a rmsd among the six solutions of less than
2.5 Å were deemed to be geometries that recognize HCII
highly consistently. Such D6 topologies were considered as
“high-specificity”topologies.Adetaileddescriptionoftheproto-
col employed is provided in the Supporting Information.
Of the 192 D6 topologies that were subjected to the CVLS
analysis, only 16 satisfied the criterion of “high specificity”.
Table S1 (see Supporting Information) describes the interac-
tionsofthe16topologiesofD6withkeyaminoacidresidues
of helices A and D in HCII. The compilation reveals several
strikingfeatures.Ofthe64possible83-helixtopologiesinthe
Figure 1. Structures of dermatan sulfate hexasaccharide D6, which is known to bind to HCII, and H5, which is known to bind to AT.
Figure 2. CVLS algorithm used to study the interaction of 192 D6
topologies with HCII.r2010 American Chemical Society 283 DOI: 10.1021/ml100048y|ACS Med. Chem. Lett. 2010, 1, 281–285
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library, none docked with “high specificity”.O ft h er e m a i n -
ing 128 topologies, two 21- and 14 32-helices satisfied the
criterion. The binding modes of these 16 “high-specificity”
topologies could be segregated into two major families. The
firstmodeofbindingisparalleltohelixD(Figure3a),amode
nearly identical to that of H5 binding to AT.
24,25 The second
family of D6 topologies interacts with helix D at an angle of
roughly 60 (Figure 3b). Only three topologies fall in the first
family, while 13 comprise the latter.
The D6 topologies that dock parallel to helix D do not
interact with Arg189 and Arg193, two of the five residues
foundimportantforbindingDS.
26-28Atthesametime,they
engage Arg103, which is known not to play a role in the
DS-HCII interaction.
21,29 Thus, these three topologies were
ruled out. Of the 13 topologies that bound at ∼60 angle to
helix D, two had a 21-fold helical geometry, while the rest
were 32-fold helices. The orientation of each of these topo-
logies is similar and interacts strongly with two critical DS
binding residues: Arg184 and Arg189.
26 Yet, significant
differences arise in interactions of these topologies with
other residues of helices A and D. None of the 32-helix
topologies interact with Lys185, which is known to be an
importantresidueforDSrecognition.
21 Furthermore,atleast
five 32-helix topologies interact with Arg103, a residue
known to be not involved in DS binding.
21,29 Thus, the 11
32-helix topologies were ruled out.
This leaves only two 21-helix topologies as possible HCII
binding geometries. Of these two, only one, that is, 21-
OS23
1C43
1C4, interacts with all five key amino acid residues
known to be involved in binding to HCII (Figure 3b), while
notinteractingwithArg103andLys173,whichareknownto
be not involved in HCII recognition (see Table S1 in Support-
ingInformation).The21-
OS23
1C43
1C4topologysatisfiesallof
the known biochemical data. This binding geometry, exhi-
biting a ∼60 angle with helix D, is radically different from
that of pentasaccharide H5 binding to AT, despite a strong
degree of structural and sequence similarity between the
two serpins.
A key question to address at this point is whether rota-
meric states of the amino acid residues, especially the
positively charged Lys and Arg implicated in binding, are
likely to affect the outcome of the computational study. A
priori, the surface-exposed Lys and Arg residues are likely to
exhibit multiple rotameric states; however, the majority of
HCII residues that strongly interact with the 21-
OS23
1C43
1C4
topology show an extended side chain conformation, which
is the preferred form because of steric and/or electrostatic
forcesarisingfromneighboringresidues.Thisconformational
restriction introduced by neighboring residues appears to be
an important reason for the preferential recognition of the
21-
OS23
1C43
1C4 topology. The residues that are known to not
interact with DS also show a similar characteristic. Arg103 is
heldinplacebyahydrophobicgrooveformedbyneighboring
residues that restrict its conformational flexibility, while
Lys173 is so far away that its side chain flexibility will not
play any role. Thus, the conformational states of the side
chains constituting the DS binding site are unlikely to drasti-
cally change the outcome of the CVLS study.
Support for the validity of the “hit” 21-
OS23
1C43
1C4 topol-
ogy is provided by conformational studies of DS in solution.
Forexample,Scottetal.reportthatDSadoptsa2-foldhelical
conformation in solution using NOE spectroscopy.
30 Like-
wise, Silipo et al. report on the use of NMR and molecular
modeling study to show that a DS tetrasaccharide, very
similar to D6, exists as four major species in solution, of
whichtwohavea2-foldhelicalconformation.
31 Additionally,
the GalNpN2Ac4S and IdoAp residues of this DS tetrasac-
charide possess
4C1 and
1C4 conformations, respectively,
which are similar to the conformations of the residues
present in the “hit” D6 topology.
31
AnotherkeytestofthenovelD6bindinggeometryiswhether
it supports bridged ternary complexation with thrombin, an
importantmechanismofDSactivationofHCII.
32OverlayingD6
in the novel binding geometry (∼60 to helix D) onto the
HCII-T cocrystal structure (PDB code 1JMO
23) shows that D6
Figure 3. Putative binding modes of two D6 topologies with HCII.
Helices D and A are shown in magenta. Basic residues of HCII are
shownassticks,andtheD6sequenceisrenderedasball-and-stick.
(a) A representative parallel binding topology, 32-
2SO3
OS23
1C4. (b)
Skewed (∼60) binding “hit” topology 21-
OS23
1C43
1C4. Amino
acid, sulfate, and carboxylate atoms involved in putative D6-HCII
interactions are highlighted by using an increased van der Waals
radius. Interactions among these functional groups are indicated
using dotted lines. Labels I1-I3 and G1-G3 are saccharide residue
labels (see Figure 1). The direction of the helix D axis is shown by
an arrow. Stereoviews of both binding modes are available in the
Supporting Information (Figure S2).r2010 American Chemical Society 284 DOI: 10.1021/ml100048y|ACS Med. Chem. Lett. 2010, 1, 281–285
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isorientedinthedirectionofthrombin(Figure4).WhentheD6
sequence was extended by nine disaccharides, in which all
IdoAp residues are in the
2SO conformation, the DS oligosac-
charide chain was found to intersect with exosite II of thrombin
at Arg93, Arg101, and Lys240 (Figure 4).
Exosite II of thrombin is a well-studied GAG-binding
domain that contributes greatly to HCII as well as AT inhibi-
tion of thrombin through the bridging mechanism.
2,32 Com-
parison of the AT-Tand HCII-Tcocrystal structures shows
thatalthoughtheserpinsarestrikinglysimilar,thepositionof
thrombin in the two is dramatically different (Figure 4).I n
addition, the orientation of exosite II is also different. The
distance between centrally located thrombin exosite II re-
sidue Arg233 and Lys125 in the AT-Tsystem is about 55 Å,
while the corresponding distance between Arg233 and
Lys185 in the HCII-Tsystem is about 70 Å. Therefore, while
a GAG chain parallel to helix D of ATwould engage exosite II
in thrombin, the same chain oriented parallel of helix D of
HCIIwouldcompletelymissthrombin(Figure4).Inessence,
this analysis stronglysupports a novel60 to helix D binding
geometry of D6 onto HCII.
Several aspects of the “hit” D6 binding geometry are
interesting. In this geometry, all of the 2-OSO3
- groups of
the IdoAp2S residues (Figure 1) interact strongly with HCII,
suggestingabroadinteractioninterface.Itisknownthat2-O-
sulfated IdoAp residues are uncommon in DS GAGs. Three
successive IdoAp2S residues are even more so.
18,19,33 The
extensive interactions of this rare sequence explain why
common DS-GAG sequences (with unsulfated IdoAp) are
inactive and support the idea that the hexasaccharide
D6-HCII interaction is specific. In addition, the skewed
∼60 binding geometry also implicates the 4-OSO3
- group
of D ring and the 6-COO
- group of ring A to have strong
interactionswithHCII(Figure5).InvivostudiesinHCII-deficient
mice suggest that GalpN2Ac4S is important for HCII-dependent
antithrombotic effect,
13 thus lending support to this conclusion.
T h er e s u l t sl e a dt oah y p o t h e s i st h a tD 6v a r i a n t sd e v o i do ft h e
twokeygroups(4-OSO3
-ofDand6-COO
-ofringA)arelikelyto
recognize HCII with weak or poor affinity.
The binding geometry implicates Arg464, a hitherto un-
heraldedresidue,asbeingimportantforD6recognition.Our
resultssuggestthatArg464iscapableofrecognizingD6inall
16 topologies (Figure 5). It is the first time that Arg464 has
been implicated in specific recognition of DS and provides a
firm hypothesis for testing the CVLS-derived binding geo-
metry.BiochemicalstudieswithaArg464mutantHCIIcould
be performed to verify its involvement in the recognition of
D6 and DS.
In summary, our combinatorial virtual screening proce-
dure has identified a novel binding geometry for a rare DS
sequence that binds HCII with high affinity. The results
suggest that this binding is specific. The novel binding
geometry(∼60angletohelixD)supportsthrombinbinding
to HCII through a template mechanism. This is the first
application of combinatorial virtual screening for DS-GAGs
and affords extraction of a “pharmacophore” involved in
DS-HCII interaction, which will greatly aid rational design
of agonists and/or antagonists directed toward HCII. Finally,
our approach is expected to be generally useful for other
GAG-serpin interactions.
SUPPORTING INFORMATION AVAILABLE Computational
experimental procedures and Table S1. This material is available
free of charge via the Internet at http://pubs.acs.org.
Figure 4. Comparison of GAG-bridged ternary complexes formed
by AT-T (yellow ribbon and tan and orange surfaces; PDB code
1TB6) and HCII-T (blue ribbon and purple surface; PDB code
1JMO). The two serpins, ATand HCII, of the two complexes were
aligned. 1TB6 also contains the GAG (heparin-like). The DS GAG
chain shown in this figure was modeled by extending the
21-
OS23
1C43
1C4 D6 geometry by nine disaccharide units (cyan
surface, IdoAp2S conformation =
2SO). The relative orientation
of Tand its exosite II (basic residues shown in red) relative to the
alignedheparinbindingsites(greensurfaces;partiallyoccluded)
is different in the two systems. See the text for details.
Figure5. Profileofinteractionsmadeby13D6topologiesthat
bind HCII at ∼60 to helix D. The level of interaction between
D6 and an amino acid residue was determined by the number
of unique interatomic distances that are less than 4.0 Å
between the nitrogen atom(s) of the basic side chain and the
sulfate or carboxylate oxygen atoms of D6 [see the Supporting
Information (Figure S1) for a representative example of this
interaction]. Interactions made by Arg464 and Arg 103 as
well as those made by three topologies that bind parallel
to helix D are not shown for clarity. The arrow highlights
topology#6(21-
OS23
1C43
1C4,seeTableS1inSupportingInformation),
which was the only topology found to interact with all amino acid
residues important for DS binding as well as not interact with Arg103.
See the text for details.r2010 American Chemical Society 285 DOI: 10.1021/ml100048y|ACS Med. Chem. Lett. 2010, 1, 281–285
pubs.acs.org/acsmedchemlett
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